OBJECTIVES: To investigate the efficacy and toxicity of single-agent erlotinib in
chemotherapy-naive castration-resistant prostate cancer. METHODS: Eligible patients …

Enzalutamide, a novel androgen receptor (AR) antagonist, prolongs overall survival of
patients with castration-resistant prostate cancer (CRPC); however, patients eventually …

Incurable castration-resistant prostate cancer (CRPC) is driven by androgen receptor (AR)
activation. Potent therapies that prevent AR signaling, such as Enzalutamide (ENZ), are …

BACKGROUND The effects of mammalian target of rapamycin (mTOR) inhibition are limited
by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …

TPS5091 Background: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal
disease with limited therapeutic options. AR targeting therapies such as enzalutamide (Enz) …

To alleviate metastatic castration-resistant prostate cancer (mCRPC), enzalutamide, a non-
steroidal antiandrogen, is employed. Following androgen deprivation therapy or anti …

Summary Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment
of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients …

Persistent androgen receptor (AR) signaling despite low levels of serum androgens has
been identified as a critical target for drug discovery in castration-resistant prostate cancer …

91 Background: Resistance to androgen receptor (AR) targeted therapies is common in
mCRPC. Glucocorticoid receptor (GR) expression increases with AR inhibition in patients …

Abstract Context Prostate cancer (PCa) is the most common noncutaneous malignancy and
the second leading cause of cancer mortality amongst men in the Western world. Up to 40 …